CA2842649C - Molecule fv multivalente de liaison a un antigene - Google Patents
Molecule fv multivalente de liaison a un antigene Download PDFInfo
- Publication number
- CA2842649C CA2842649C CA2842649A CA2842649A CA2842649C CA 2842649 C CA2842649 C CA 2842649C CA 2842649 A CA2842649 A CA 2842649A CA 2842649 A CA2842649 A CA 2842649A CA 2842649 C CA2842649 C CA 2842649C
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- domain
- binding molecule
- binding
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Dans un aspect, la présente invention concerne une molécule de liaison à un antigène spécifique pour l'albumine et CD3, comprenant deux chaînes polypeptidiques, chaque chaîne polypeptidique ayant au moins quatre domaines variables dans une orientation empêchant la formation de Fv et les deux chaînes polypeptidiques étant dimérisées l'une avec l'autre, formant ainsi une molécule multivalente de liaison à un antigène. Sur chacune des deux chaînes polypeptidiques, les quatre domaines variables sont disposés dans l'ordre VLA-VHB-VLB-VHA à partir de l'extrémité N-terminale à l'extrémité C-terminale du polypeptide. La présente invention concerne également des compositions de la molécule de liaison à un antigène et les procédés d'utilisation de la molécule de liaison à un antigène ou les compositions de celle-ci pour le traitement de diverses maladies.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/062673 WO2013013700A1 (fr) | 2011-07-22 | 2011-07-22 | Molécule fv multivalente de liaison à un antigène |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2842649A1 CA2842649A1 (fr) | 2013-01-31 |
CA2842649C true CA2842649C (fr) | 2020-01-21 |
Family
ID=44719851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2842649A Active CA2842649C (fr) | 2011-07-22 | 2011-07-22 | Molecule fv multivalente de liaison a un antigene |
Country Status (8)
Country | Link |
---|---|
JP (1) | JP5938473B2 (fr) |
CN (1) | CN103687879B (fr) |
AU (1) | AU2011373925B2 (fr) |
BR (1) | BR112014001573B8 (fr) |
CA (1) | CA2842649C (fr) |
MX (1) | MX347829B (fr) |
RU (1) | RU2613368C2 (fr) |
WO (1) | WO2013013700A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10647768B2 (en) | 2014-05-29 | 2020-05-12 | Macrogenics, Inc. | Multi-chain polypeptide-containing tri-specific binding molecules |
JP2017520575A (ja) | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
KR20170105622A (ko) | 2015-01-26 | 2017-09-19 | 마크로제닉스, 인크. | Dr5-결합 도메인을 포함하는 다가 분자 |
CN108289949B (zh) | 2015-05-29 | 2022-04-12 | 安普希韦纳治疗公司 | 双特异性cd33和cd3结合蛋白质的使用方法 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
LT3328419T (lt) | 2015-07-30 | 2021-11-10 | Macrogenics, Inc. | Pd-1 surišančios molekulės ir jų panaudojimo būdai |
EP3389714A4 (fr) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ror1-結合分子及其使用方法 |
IL262396B2 (en) | 2016-04-15 | 2023-09-01 | Macrogenics Inc | New b7-h3 binding molecules, drug-antibody conjugates and their uses |
EP3558368A4 (fr) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | Molécules de liaison à adam9 et leurs procédés d'utilisation |
KR20240023449A (ko) | 2017-02-08 | 2024-02-21 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
EP4273258A3 (fr) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Protéines se liant à her2, nkg2d et cd16 |
WO2018158349A1 (fr) * | 2017-02-28 | 2018-09-07 | Affimed Gmbh | Di-anticorps en tandem pour la mise en contact de cellules nk dirigées par cd16a |
EP3635014B1 (fr) * | 2017-06-05 | 2023-09-27 | Numab Therapeutics AG | Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa |
JP7087072B2 (ja) | 2017-10-26 | 2022-06-20 | サン-ゴバン グラス フランス | 統合されたカメラモジュールを有するアドオン部品 |
RU2020122822A (ru) | 2017-12-12 | 2022-01-13 | Макродженикс, Инк. | Биспецифичные связывающие cd16 молекулы и их применение при лечении заболеваний |
JP2021512630A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Nkg2d受容体を標的とする抗体可変ドメイン |
JP7337079B2 (ja) | 2018-02-15 | 2023-09-01 | マクロジェニクス,インコーポレーテッド | 変異型cd3結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
CA3102562A1 (fr) * | 2018-06-07 | 2019-12-12 | Cullinan Management, Inc. | Proteines de liaison multi-specifiques et procedes d'utilisation associes |
RU2738802C1 (ru) | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0672142B1 (fr) | 1992-12-04 | 2001-02-28 | Medical Research Council | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
WO2003087163A1 (fr) * | 2002-04-15 | 2003-10-23 | Chugai Seiyaku Kabushiki Kaisha | Procede d'elaboration d'une banque scdb |
ES2559763T3 (es) | 2002-09-10 | 2016-02-15 | Affimed Gmbh | Anticuerpo humano específico de CD3 con propiedades inmunosupresoras |
EP1710255A4 (fr) * | 2003-12-12 | 2008-09-24 | Chugai Pharmaceutical Co Ltd | Anticorps modifies reconnaissant un recepteur trimere ou plus grand |
TW200722518A (en) * | 2005-03-31 | 2007-06-16 | Chugai Pharmaceutical Co Ltd | Sc(fv)2 structural isomers |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
JP5725508B2 (ja) * | 2009-03-25 | 2015-05-27 | 国立大学法人東北大学 | Lh型二重特異性抗体 |
PT2361936T (pt) * | 2010-02-25 | 2016-07-15 | Affimed Gmbh | Molécula que se liga a antigénio e utilizações desta |
-
2011
- 2011-07-22 RU RU2013157040A patent/RU2613368C2/ru active
- 2011-07-22 CN CN201180072477.5A patent/CN103687879B/zh active Active
- 2011-07-22 CA CA2842649A patent/CA2842649C/fr active Active
- 2011-07-22 BR BR112014001573A patent/BR112014001573B8/pt active IP Right Grant
- 2011-07-22 MX MX2014000816A patent/MX347829B/es active IP Right Grant
- 2011-07-22 WO PCT/EP2011/062673 patent/WO2013013700A1/fr active Application Filing
- 2011-07-22 AU AU2011373925A patent/AU2011373925B2/en not_active Ceased
- 2011-07-22 JP JP2014520541A patent/JP5938473B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BR112014001573B1 (pt) | 2022-08-30 |
AU2011373925A1 (en) | 2014-01-16 |
JP2014527515A (ja) | 2014-10-16 |
JP5938473B2 (ja) | 2016-06-22 |
RU2613368C2 (ru) | 2017-03-16 |
BR112014001573A2 (pt) | 2017-02-21 |
RU2013157040A (ru) | 2015-08-27 |
CN103687879B (zh) | 2016-05-04 |
CN103687879A (zh) | 2014-03-26 |
CA2842649A1 (fr) | 2013-01-31 |
MX347829B (es) | 2017-05-15 |
MX2014000816A (es) | 2014-07-09 |
BR112014001573B8 (pt) | 2022-11-08 |
AU2011373925B2 (en) | 2016-04-28 |
WO2013013700A1 (fr) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2842649C (fr) | Molecule fv multivalente de liaison a un antigene | |
US20180346590A1 (en) | Antigen-binding molecule and uses thereof | |
EP2371866B1 (fr) | Molécule Fv de liasion polyvalente aux antigènes | |
US20180222996A1 (en) | Bispecific scfv immunofusion (bif) | |
CN107001468B (zh) | Cd3结合结构域 | |
JP2018525347A (ja) | 癌免疫療法に使用するための二重特異性抗体 | |
WO2022022709A1 (fr) | PROTÉINE DE FUSION SIRPα-FC | |
TWI830761B (zh) | 針對cldn18.2和cd3之抗體構建體 | |
CA3211935A1 (fr) | Anticorps anti-antigene du virus de la vaccine et compositions et procedes associes | |
CN117836321A (zh) | 抗牛痘病毒抗原抗体以及相关组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140325 |